Frederic Triebel - Prima Biomed Chief Scientific Officer & Chief Medical Officer
Executive
Dr. Frederic Triebel, M.D., Ph.D., serves as Chief Scientific Officer Chief Medical Officer of the Company. He was the scientific founder of Immutep S.A. and served as the Scientific and Medical Director at Immutep from 2004. Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy, a large cancer centre in Paris, he discovered the LAG3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological followup of cancer patients treated in Phase III immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Prof. Triebel holds a Ph.D. in immunology and successfully developed several research programs in immunogenetics and immunotherapy, leading to 144 publications and 16 patents. since 2014.
| Age | 60 |
| Tenure | 10 years |
| Phone | 61 2 8315 7003 |
| Web | http://www.primabiomed.com.au |
Prima Biomed Management Efficiency
The company has return on total asset (ROA) of (15.25) % which means that it has lost $15.25 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (30.29) %, meaning that it created substantial loss on money invested by shareholders. Prima Biomed's management efficiency ratios could be used to measure how well Prima Biomed manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 4.6 M in liabilities with Debt to Equity (D/E) ratio of 21.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed has a current ratio of 5.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prima Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, Prima Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prima Biomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prima to invest in growth at high rates of return. When we think about Prima Biomed's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Wendy Tse | Yips Chemical Holdings | N/A | |
| Wing Leung | Yips Chemical Holdings | 46 | |
| Christopher Lewis | The Mosaic | 62 | |
| Kwan Ip | Yips Chemical Holdings | 40 | |
| David Mangine | Hawkins | N/A | |
| Qingmei Wang | HUTCHMED DRC | 61 | |
| Sandra Frithiof | Calliditas Therapeutics | 49 | |
| Teona Johnson | Calliditas Therapeutics | N/A | |
| David Ng | HUTCHMED DRC | N/A | |
| Drew Grahek | Hawkins | 53 | |
| Paul Siler | Hawkins | N/A | |
| Brian Gorman | Calliditas Therapeutics | 48 | |
| David Ferraro | Calliditas Therapeutics | N/A | |
| Ping Fung | Yips Chemical Holdings | 59 | |
| Richard MD | Calliditas Therapeutics | 60 | |
| Selina Zhang | HUTCHMED DRC | N/A | |
| Paul CFA | The Mosaic | N/A | |
| Kin MBA | HUTCHMED DRC | 47 | |
| Walter III | The Mosaic | 60 | |
| Shun Feng | Yips Chemical Holdings | 42 | |
| Hong Chen | HUTCHMED DRC | 54 | |
Management Performance
| Return On Equity | -30.29 | |||
| Return On Asset | -15.25 |
Prima Biomed Leadership Team
Elected by the shareholders, the Prima Biomed's board of directors comprises two types of representatives: Prima Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prima. The board's role is to monitor Prima Biomed's management team and ensure that shareholders' interests are well served. Prima Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prima Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pete Meyers, Non-Executive Director | ||
| Russell Howard, Non-Executive Director | ||
| Larisa Chisholm, Director of Industry Liaison and Devel. and Director of Intellectual Property | ||
| Tom Bloomfield, Joint Company Secretary | ||
| YueLing Wong, Non-Executive Deputy Chairman of the Board | ||
| Frederic Triebel, Chief Scientific Officer & Chief Medical Officer | ||
| Deanne Miller, General Counsel, Company Secretary | ||
| Sharron Gargosky, Chief Technical Officer | ||
| Grant Chamberlain, Non-Executive Director | ||
| Lucy Turnbull, Non-Executive Chairman of the Board | ||
| Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee | ||
| Matthew Gregorowski, IR Contact Officer |
Prima Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prima Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -30.29 | |||
| Return On Asset | -15.25 | |||
| Profit Margin | (227.54) % | |||
| Operating Margin | (229.73) % | |||
| Current Valuation | 38.96 M | |||
| Shares Owned By Institutions | 4.39 % | |||
| Number Of Shares Shorted | 137.1 K | |||
| Price To Earning | (5.70) X | |||
| Price To Book | 1.71 X | |||
| Price To Sales | 14.25 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Prima Biomed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Prima Biomed's short interest history, or implied volatility extrapolated from Prima Biomed options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prima Biomed using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Prima Stock
If you are still planning to invest in Prima Biomed check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prima Biomed's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |